Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) shares were up 4.3% during trading on Wednesday . The stock traded as high as $3.67 and last traded at $3.65, with a volume of 266,562 shares. The stock had previously closed at $3.50.

The company has a 50-day moving average of $3.50 and a 200 day moving average of $4.46. The firm’s market capitalization is $226.31 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.48. The firm earned $8.10 million during the quarter, compared to the consensus estimate of $9.70 million. The firm’s quarterly revenue was up 84.1% on a year-over-year basis. On average, analysts forecast that Aralez Pharmaceuticals Inc. will post ($1.00) EPS for the current year.

In other news, Director Arthur S. Kirsch purchased 27,500 shares of the business’s stock in a transaction dated Thursday, May 12th. The stock was bought at an average price of $3.49 per share, for a total transaction of $95,975.00. Following the purchase, the director now owns 96,609 shares of the company’s stock, valued at $337,165.41. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James Patrick Tursi purchased 10,000 shares of the business’s stock in a transaction dated Friday, May 20th. The shares were purchased at an average price of $3.75 per share, with a total value of $37,500.00. Following the purchase, the insider now directly owns 179,368 shares in the company, valued at approximately $672,630. The disclosure for this purchase can be found here.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.